Target intelligence / Profile preview

Endoplasmic reticulum alpha-glucosidase I (for α-glucosidase I) and Endoplasmic reticulum alpha-glucosidase II (for α-glucosidase II) (ER α-glucosidase I (for I), ER α-glucosidase II (for II))

Target
ER α-glucosidase I (for I), ER α-glucosidase II (for II)
Molecular classification
Enzyme, Glycoside hydrolase family 63 (I) or family 31 (II)
01

Overview

Endoplasmic reticulum alpha-glucosidase I (GCSI) and alpha-glucosidase II (GCSII) are resident enzymes of the endoplasmic reticulum that catalyze sequential glucose trimming steps from the N-linked glycans on newly synthesized glycoproteins. α-Glucosidase I removes the outermost (terminal) glucose residue, while α-glucosidase II, a heterodimer composed of catalytic (α) and regulatory (β) subunits, removes the two innermost α1,3-linked glucose residues. This processing is essential for glycoprotein folding, maturation, and quality control, facilitating interaction with molecular chaperones such as calnexin and calreticulin. Both enzymes are validated drug targets for modulation of viral infectivity (by misfolding viral glycoproteins) and potentially other diseases involving secretory protein processing.

Other names
α-glucosidase I (also known as glucosidase I, GCSI, EC 3.2.1.106)α-glucosidase II (also known as glucosidase II, GCSII, EC 3.2.1.84)
02

Mechanism of action

Inhibitors block sequential glucose trimming steps required for proper glycoprotein folding, resulting in misfolded glycoproteins and reduced infectivity or cell viability

03

Biological functions

N-linked glycoprotein processingProtein quality control in the endoplasmic reticulumGlycoprotein folding and maturation
04

Disease associations

Infection (especially viral infections, e.g., hepatitis C, dengue)Cancer (targeted for disrupting glycoprotein folding)Other (rare congenital disorders of glycosylation)
05

Safety considerations

Potential for off-target effects and global disruption of secretory protein quality control leading to toxicity in non-target tissuesGastrointestinal and systemic effects from inhibition of similar enzymes in non-ER locations
06

Interacting drugs

Iminosugars, such as castanospermine, 1-deoxynojirimycin, N-butyl-deoxynojirimycin, and derivatives (e.g. celgosivir)
07

Biomarkers

Accumulation of specific glucosylated oligosaccharide intermediates (monoglucosylated or triglucosylated species in cell extracts)

Beyond the preview

Go deeper on Endoplasmic reticulum alpha-glucosidase I (for α-glucosidase I) and Endoplasmic reticulum alpha-glucosidase II (for α-glucosidase II) (ER α-glucosidase I (for I), ER α-glucosidase II (for II)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endoplasmic reticulum alpha-glucosidase I (for α-glucosidase I) and Endoplasmic reticulum alpha-glucosidase II (for α-glucosidase II) (ER α-glucosidase I (for I), ER α-glucosidase II (for II)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call